What are the recommendations for pneumococcal vaccinations for the prevention of bacterial pneumonia?

Updated: Sep 30, 2020
  • Author: Justina Gamache, MD; Chief Editor: Guy W Soo Hoo, MD, MPH  more...
  • Print

On October 12, 2012, the Advisory Committee on Immunization Practices (ACIP) published updated recommendations for pneumococcal vaccination of high-risk adults. The committee recommends routine use of Prevnar 13 in addition to the previously recommended Pneumovax 23 for adults aged 19 years and older with immunocompromising conditions (eg, HIV, cancer, renal disease), functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants. Patients who have not previously received either vaccine should be given one dose of Prevnar 13 followed by one dose of Pneumovax 23 after at least eight weeks. In patients who have previously received Pneumovax 23 vaccine, administer one dose of Prevnar 13 at least one year after the last Pneumovax 23 dose. [74]

On August 13, 2014, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended routine use of pneumococcal vaccine 13-valent (PCV13 [Prevnar 13]) among adults aged 65 years and older. [75] PCV13 should be administered in series with the 23-valent pneumococcal vaccine polyvalent (PPSV23 [Pneumovax23]), the vaccine currently recommended for adults aged 65 years and older. PCV13 was approved by the Food and Drug Administration (FDA) in late 2011 for use among adults aged 50 years and older. In June 2014, the results of a randomized placebo-controlled trial evaluating efficacy of PCV13 for preventing community-acquired pneumonia among approximately 85,000 adults aged 65 years and older with no prior pneumococcal vaccination history (CAPiTA trial) became available and were presented to ACIP. [76]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!